INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Verzoni Elena

Main Facility: Oncologia Medica Genitourinaria

Drug: Xaluritaming + Abiraterone versus Docetaxel, Cabazitaxel e Abiraterone

Pathologies: Prostate tumors

This is a randomized, multicenter, open-label, phase 3 study to compare the efficacy and safety of xaluritamig plus abiraterone against investigator’s choice of docetaxel, cabazitaxel, or abiraterone in participants with chemotherapy-naïve mCRPC.

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe